Shares of Veru VERU rose 4% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share decreased 25.00% year over year to ($0.05), which missed the estimate of ($0.03).
Revenue of $10,322,000 higher by 6.12% year over year, which missed the estimate of $10,970,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 13, 2020
Time: 08:00 AM
ET Webcast URL: https://verupharma.com/investors/
Price Action
Company's 52-week high was at $4.74
52-week low: $1.67
Price action over last quarter: down 24.38%
Company Overview
Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Commercial; and Research and Development.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.